Details

Autor(en) / Beteiligte

• Sashidharan, Nithin
• Shenoy, Smita
• Kishore, Meena Kumari Kamal
• Thanusubramanian, Harish

Titel

Comparison of Two Therapeutic Regimes, Lenalidomide with Dexamethasone and Thalidomide with Dexamethasone, in the Treatment of Multiple Myeloma at a Tertiary Care Hospital in India

Ist Teil von

• Journal of clinical and diagnostic research, 2015-05, Vol.9 (5), p.XC01-XC04

Ort / Verlag

India: JCDR Research and Publications Private Limited

Erscheinungsjahr

2015

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Multiple myeloma accounts for 1% of all neoplastic disorders and 10% of all haematological malignancies. Drugs like thalidomide, lenalidomide and bortezomib have emerged as active drugs in the treatment of multiple myeloma.There are few studies which have compared thalidomide-dexamethasone (thal/dex) and lenalidomide-dexamethasone (len/dex) in the treatment of multiple myeloma in Indian scenario. To compare the efficacy and the adverse events observed with thalidomide-dexamethasone and lenalidomide-dexamethasone in the treatment of newly diagnosed cases of multiple myeloma. Observational Study conducted in tertiary care centre. The case record files of patients from the year January 2006 to July 2011 with diagnosis of multiple myeloma were studied. Primarily Descriptive. There was no significant difference between thal/dex and len/dex treatment groups with respect to efficacy and safety in our study. Studies with larger sample size and a longer follow up to compare efficacy and safety of thal/dex and len/dex in treatment of multiple myeloma are required to be carried out to provide significant results.